Merch
Medical card
For the first time, a federal program could give Medicare patients access to hemp-derived CBD at no cost. Here’s how the CMS pilot works, who may be eligible, and what to know before it launches.
As early as April 1, 2026, some Medicare patients may be able to receive hemp-derived CBD (cannabidiol) products at no cost through a new federal pilot program, the closest thing to Medicare CBD coverage the federal government has offered. CMS Administrator Dr. Mehmet Oz announced in December 2025 that “millions of Americans on Medicare” would become eligible. The operational details paint a narrower picture: a voluntary pilot where participating healthcare organizations, not Medicare, would foot the bill, limited to specific care models, and facing a collision with federal hemp restrictions set to take effect in November 2026.
The Medicare CBD coverage pilot is a CMS initiative set to launch April 1, 2026, that would allow participating healthcare organizations to furnish hemp-derived CBD products, worth up to $500 per year, to eligible Medicare beneficiaries at no cost to the patient.
How the Medicare CBD Coverage Pilot Works
CMS authorized the CMS CBD program through a Substance Access Beneficiary Engagement Incentive (BEI), available to organizations in three CMS Innovation Center models: ACO REACH, the Enhancing Oncology Model, and the upcoming LEAD Model. The final program rules, published March 23, 2026, outline these boundaries:
- Participating organizations could spend up to $500 per beneficiary per year on CBD products. Medicare would not reimburse these costs; the organization would absorb them.
- Products must be orally administered, contain no more than 0.3% delta-9 THC, and cap at 3 milligrams of total tetrahydrocannabinols per serving. Inhalable products are excluded.
- A qualified physician affiliated with the organization must furnish products. Patients could not buy retail CBD and seek reimbursement.
- All products require third-party testing for potency, contaminants, and microbial hazards.
- ACO REACH and Enhancing Oncology participants could begin as early as April 1, 2026. LEAD Model participants wouldn’t start until January 1, 2027.
The Political Path to Medicare CBD Coverage
This initiative didn’t start with a clinical breakthrough. Howard Kessler, a Palm Beach billionaire and Trump ally, founded The Commonwealth Project in 2019 and leveraged personal ties to the president to press for cannabis reform. After HHS Secretary Robert F. Kennedy Jr. met with Kessler, CMS moved to authorize CBD coverage. At the December 2025 signing ceremony, Kennedy said the program wouldn’t exist without Kessler’s advocacy.
On December 18, 2025, Trump signed an executive order titled “Increasing Medical Marijuana and Cannabidiol Research,” directing the Attorney General to advance cannabis rescheduling from Schedule I to Schedule III. The order does not reschedule cannabis on its own; it accelerates an existing process that remains pending.
What the Research Says About CBD for Seniors
Clinical evidence supporting CBD for seniors remains limited. A 2025 review in Frontiers in Psychiatry found that human trials on CBD and cognition have focused on young healthy adults, with few studies examining older populations. A 2024 meta-analysis in Age and Ageing pooling 58 randomized controlled trials (6,611 participants aged 50+) found that cannabinoid-based medicines appear generally safe and acceptable in middle-aged and older adults, though THC dose-dependently increased dizziness, balance problems, and somnolence, all concerning for fall risk.
Drug interactions present another concern for this population. Researchers at Penn State identified 139 medications that may interact with cannabinoids, narrowing to 57 where altered concentration could be dangerous. Older adults face elevated risk because they tend to take multiple medications and experience age-related changes in how their bodies metabolize drugs.
What’s Next for the CMS CBD Program
The program’s trajectory depends on whether ACOs choose to participate and absorb product costs, whether Congress amends the November 2026 hemp redefinition, and whether organizations can source products that satisfy both CMS rules and incoming federal standards. Companies are already positioning for the opportunity: Charlotte’s Web announced plans to deliver products through an online healthcare portal, and Cornbread Hemp secured a supplier contract through the Alliant Purchasing GPO, which serves 68,000 healthcare provider locations.
The Medicare CBD coverage pilot could mark a first step toward integrating hemp-derived products into federal healthcare. The gap between the program’s political ambitions and its regulatory, scientific, and operational realities remains wide. If you’re a Medicare beneficiary considering CBD through this program, talk to your physician about drug interactions and confirm whether your healthcare organization plans to participate.
Frequently Asked Questions
Does Medicare now pay for CBD products?
Not yet. Medicare CBD coverage does not exist in the traditional sense. Under the proposed CBD pilot program, participating healthcare organizations, not Medicare, would furnish CBD products at their own expense, up to $500 per beneficiary per year.
Could I buy CBD at a dispensary or store and get reimbursed?
No. Under the pilot’s published rules, a qualified physician affiliated with a participating organization would need to furnish the products. Retail purchases would not be eligible.
Would CBD edibles or vapes be covered?
Based on the published rules, only orally administered products (such as tinctures, capsules, and oils) would be eligible. The pilot excludes inhalable products, and all eligible items must contain no more than 3 milligrams of total THC per serving.
Could the federal hemp law shut down the pilot?
It could. The November 2026 hemp redefinition caps THC at 0.4 milligrams per container, while the CMS CBD program allows 3 milligrams per serving. Unless Congress amends the law or creates an exemption, most products eligible under the pilot may become federally noncompliant.
Am I eligible for the Medicare CBD pilot program?
Eligibility depends on your healthcare organization, not your individual Medicare plan. You may be eligible if you receive care through an organization participating in CMS’s ACO REACH model, the Enhancing Oncology Model, or (starting January 2027) the LEAD Model. Ask your provider whether they’ve opted into the CBD pilot program.
Is CBD safe for seniors taking other medications?
CBD for seniors carries specific risks around drug interactions. Researchers have identified 57 medications where cannabinoid interactions could be dangerous. Older adults should discuss CBD with their physician, especially if they take blood thinners, heart medications, or drugs metabolized by the liver’s cytochrome P450 enzymes.
Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.
